CTM
Castellum, Inc.·Technology
0.73
4.051%(+0.03)
Market ClosedLast Updated: — ET
52W L: $0.4852W H: $1.56
CTM NEWS
globenewswire.com
Mar 10
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.
globenewswire.com
Mar 4
Castellum, Inc. Announces 2025 Unaudited Financial Results
VIENNA, Va., March 04, 2026 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum” “CTM”, “we” or the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces certain unaudited highlights of its operating results for its year ended December 31, 2025.
seekingalpha.com
Feb 18
Castellum AB (publ) (CWQXY) Q4 2025 Earnings Call Transcript
Castellum AB (publ) (CWQXY) Q4 2025 Earnings Call Transcript
globenewswire.com
Feb 17
Castellum, Inc. Pays Off All Debt
VIENNA, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) ("Castellum" or "CTM"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that it has retired in full the $400,000 principal balance on its sole remaining note payable to Emil Kaunitz.
